Candesartan Effectively Preserves Cognition in Senescence Accelerated Mouse Prone 8 (SAMP8) Mice

Overview

Journal J Alzheimers Dis Rep

Publisher IOS Press

Date 2022 Jul 27

PMID 35891637

Authors

Heba A Ahmed

Tauheed Ishrat

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD) has become a worldwide crisis with no effective therapeutic options. The medications currently available for AD are only palliative; their effect is temporary, and they are associated with unfavorable side effects. Even the newest medication aducanumab, granted accelerated FDA approval in 2021, failed to show cognitive benefits in clinical trials and continued approval requires verification in subsequent clinical trials. There is an urgent need for safe and effective therapies to preserve cognition and effectively manage AD. Generally, a new drug product takes several years for FDA approval and exceeds 2.5 billion dollars in research and development, with most new drug products never even reaching the market. This has led to a recent shift for repurposing/repositioning existing FDA-approved medications, to new therapeutic indications.

Objective: To investigate the effects of long-term treatment with candesartan, an FDA-approved angiotensin-II type-1 receptor blocker (ARB), on the development of cognitive impairment associated with premature aging.

Methods: Candesartan was given at a dose of 1 mg/kg/d in an AD model of senescence-accelerated mouse prone-8 (SAMP8) and senescence-accelerated mouse resistant (SAMR1) mice. Oral treatment with candesartan or vehicle was started, in 2-month-old mice and administered continuously for 4-months.

Results: Low-dose candesartan prevented the development of cognitive impairment, otherwise associated with accelerated aging, in SAMP8 mice, by reducing inflammation and nitro-oxidative stress. Candesartan did not affect the cognitive function of control SAMR1 mice.

Conclusion: Early ARB treatment might be beneficial in preventing age-related cognitive deficits in AD-prone individuals.

References

Gally F, Rao D, Schmitz C, Colvin K, Yeager M, Perraud A . The TRPM2 ion channel contributes to cytokine hyperproduction in a mouse model of Down Syndrome. Biochim Biophys Acta Mol Basis Dis. 2017; 1864(1):126-132. DOI: 10.1016/j.bbadis.2017.09.025. View

Timaru-Kast R, Wyschkon S, Luh C, Schaible E, Lehmann F, Merk P . Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma*. Crit Care Med. 2011; 40(3):935-44. DOI: 10.1097/CCM.0b013e31822f08b9. View

Braszko J, Wincewicz D, Jakubow P . Candesartan prevents impairment of recall caused by repeated stress in rats. Psychopharmacology (Berl). 2012; 225(2):421-8. PMC: 3537078. DOI: 10.1007/s00213-012-2829-3. View

Guerrero A, De Strooper B, Arancibia-Carcamo I . Cellular senescence at the crossroads of inflammation and Alzheimer's disease. Trends Neurosci. 2021; 44(9):714-727. DOI: 10.1016/j.tins.2021.06.007. View

Ahmed H, Ishrat T, Pillai B, Fouda A, Sayed M, Eldahshan W . RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial. J Neuroinflammation. 2018; 15(1):229. PMC: 6090822. DOI: 10.1186/s12974-018-1262-x. View

Flores J, Noel A, Foveau B, Lynham J, Lecrux C, LeBlanc A . Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer's disease mouse model. Nat Commun. 2018; 9(1):3916. PMC: 6156230. DOI: 10.1038/s41467-018-06449-x. View

Sanchez-Lemus E, Honda M, Saavedra J . Angiotensin II AT1 receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress. Behav Brain Res. 2012; 232(1):84-92. PMC: 3372928. DOI: 10.1016/j.bbr.2012.03.041. View

Abouhish H, Thounaojam M, Jadeja R, Gutsaeva D, Powell F, Khriza M . Inhibition of HDAC6 Attenuates Diabetes-Induced Retinal Redox Imbalance and Microangiopathy. Antioxidants (Basel). 2020; 9(7). PMC: 7402090. DOI: 10.3390/antiox9070599. View

Qie S, Ran Y, Lu X, Su W, Li W, Xi J . Candesartan modulates microglia activation and polarization via NF-κB signaling pathway. Int J Immunopathol Pharmacol. 2020; 34:2058738420974900. PMC: 7691946. DOI: 10.1177/2058738420974900. View

10.

Lopez-Ramos J, Jurado-Parras M, Sanfeliu C, Acuna-Castroviejo D, Delgado-Garcia J . Learning capabilities and CA1-prefrontal synaptic plasticity in a mice model of accelerated senescence. Neurobiol Aging. 2011; 33(3):627.e13-26. DOI: 10.1016/j.neurobiolaging.2011.04.005. View

11.

Ma J, Xiong J, Hou W, Yan H, Sun Y, Huang S . Protective effect of carnosine on subcortical ischemic vascular dementia in mice. CNS Neurosci Ther. 2012; 18(9):745-53. PMC: 6493405. DOI: 10.1111/j.1755-5949.2012.00362.x. View

12.

Lovell M, Xie C, Gabbita S, Markesbery W . Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic Biol Med. 2000; 28(3):418-27. DOI: 10.1016/s0891-5849(99)00258-0. View

13.

Ding M, Cavallin A, Hermansson N, Berntsson P, Jinton L, Rodrigo Blomqvist S . Comparing Flow Cytometry QBeads PlexScreen Assays with Other Immunoassays for Determining Multiple Analytes. SLAS Discov. 2018; 23(7):676-686. DOI: 10.1177/2472555218771610. View

14.

Ahmed H, Ishrat T . The Brain AT2R-a Potential Target for Therapy in Alzheimer's Disease and Vascular Cognitive Impairment: a Comprehensive Review of Clinical and Experimental Therapeutics. Mol Neurobiol. 2020; 57(8):3458-3484. PMC: 8109287. DOI: 10.1007/s12035-020-01964-9. View

15.

Kozak W, Kozak A, Johnson M, Elewa H, Fagan S . Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. J Pharmacol Exp Ther. 2008; 326(3):773-82. DOI: 10.1124/jpet.108.139618. View

16.

Villapol S, Yaszemski A, Logan T, Sanchez-Lemus E, Saavedra J, Symes A . Candesartan, an angiotensin II AT₁-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. Neuropsychopharmacology. 2012; 37(13):2817-29. PMC: 3499714. DOI: 10.1038/npp.2012.152. View

17.

McKhann G, Knopman D, Chertkow H, Hyman B, Jack Jr C, Kawas C . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):263-9. PMC: 3312024. DOI: 10.1016/j.jalz.2011.03.005. View

18.

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

19.

Sawano E, Negishi T, Aoki T, Murakami M, Tashiro T . Alterations in local thyroid hormone signaling in the hippocampus of the SAMP8 mouse at younger ages: association with delayed myelination and behavioral abnormalities. J Neurosci Res. 2012; 91(3):382-92. PMC: 3588156. DOI: 10.1002/jnr.23161. View

20.

Huang L, Chao S, Hu C . Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020; 27(1):18. PMC: 6943903. DOI: 10.1186/s12929-019-0609-7. View